A PYMNTS Company

Allergan With Settle With Restasis Payers For $30M

By  |  October 12, 2021

AbbVie subsidiary Allergan will pay about US$30 million to resolve the remainder of a consolidated antitrust class action over its alleged scheme to delay generic versions of the dry-eye treatment Restasis, according to a federal court filing in Brooklyn.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The insurers and pension funds leading part of the lawsuit sought preliminary approval from Judge Nina Gershon for the US$29,999,999.99 settlement on behalf of “end payers” that completely or partially covered consumer sales of the drug.

    The October 8 request comes about four months after Gershon paused the case while the two sides hammered out a final deal.

    The proposed class action settlement was disclosed in a filing on Tuesday, October 12, in federal court in Brooklyn and would resolve claims by direct purchasers of Restasis such as wholesalers who claimed that Allergan’s actions led them to be overcharged for the drug.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.